-
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
NCT06297590 ·
Phase: Phase 1 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 10 locations
-
A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants
NCT06786676 ·
Phase: Phase 1 ·
Ages: 19 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
NCT07230652 ·
Phase: Phase 1 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy
NCT07580703 ·
Phase: Phase 1 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
NCT06619613 ·
Phase: Phase 1 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
A Study of LY3439539 in Participants With Alzheimer's Disease
NCT07598370 ·
Phase: Phase 1 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 11 locations
-
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768 ·
Phase: Phase 1 ·
Ages: 45 Years to 85 Years ·
Sex: All (male and female) · 13 locations
-
A Study of Psychedelics in Healthy Older Adults With Low Well-being
NCT07386730 ·
Phase: Phase 1 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
NCT06995573 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 10 locations
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106 ·
Phase: Phase 1, Phase 2 ·
Ages: 35 Years to 85 Years ·
Sex: All (male and female) · 26 locations
-
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
NCT07599670 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years to 90 Years ·
Sex: All (male and female) · 12 locations
-
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
NCT07214727 ·
Phase: Phase 1 ·
Ages: 40 Years to 80 Years ·
Sex: All (male and female) · 13 locations
-
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
NCT05231785 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 8 locations
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
NCT07758595 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 4 locations
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT07234942 ·
Phase: Phase 1 ·
Ages: 50 Years to 75 Years ·
Sex: All (male and female) · 12 locations
-
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
NCT06372821 ·
Phase: Phase 1 ·
Ages: 21 Years to 80 Years ·
Sex: All (male and female) · 2 locations
-
A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.
NCT07218081 ·
Phase: Phase 1 ·
Ages: 65 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
NCT07158905 ·
Phase: Phase 1 ·
Ages: 65 Years to 80 Years ·
Sex: All (male and female) · 6 locations
-
Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
NCT07367815 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study
NCT07332260 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
NCT07764146 ·
Phase: Phase 1 ·
Ages: 30 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
Assess Fibrin in Brains With AD/ADRD
NCT05336695 ·
Phase: Phase 1, Phase 2 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
NCT05667649 ·
Phase: Phase 1 ·
Ages: 45 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
NCT06535308 ·
Phase: Phase 1 ·
Ages: 19 Years to 45 Years ·
Sex: All (male and female) · 1 location
-
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NCT06189963 ·
Phase: Phase 1, Phase 2 ·
Ages: 40 Years to 85 Years ·
Sex: All (male and female) · 8 locations
-
Evaluation of the Safety, Tolerability, and Pharmacokinetics of J4 in Healthy Adults
NCT06938763 ·
Phase: Phase 1 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female) · 1 location
-
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
NCT06999434 ·
Phase: Phase 1 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
NCT05374278 ·
Phase: Phase 1, Phase 2 ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
Innate Immunity Stimulation Via TLR9 in Early AD
NCT05606341 ·
Phase: Phase 1 ·
Ages: 60 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
NCT07651319 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years to 86 Years ·
Sex: All (male and female) · 1 location
-
Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)
NCT06597942 ·
Phase: Phase 1, Phase 2 ·
Ages: 55 Years to 100 Years ·
Sex: All (male and female) · 1 location
-
Low-Dose Radiotherapy for Alzheimer's Disease
NCT07693140 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 1 location
-
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
NCT04684602 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
NCT06582706 ·
Phase: Phase 1, Phase 2 ·
Ages: 60 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
NCT02649985 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873 ·
Phase: Phase 1 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female) · 2 locations
-
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT07169630 ·
Phase: Phase 1 ·
Ages: 50 Years to 100 Years ·
Sex: All (male and female) · 1 location
-
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
NCT04500847 ·
Phase: Phase 1 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 2 locations
-
Rifaximin SSD in Dementia Trial
NCT06718686 ·
Phase: Phase 1, Phase 2 ·
Ages: 65 Years and older ·
Sex: All (male and female) · 1 location
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
NCT05591027 ·
Phase: Phase 1 ·
Ages: 60 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease
NCT06585384 ·
Phase: Phase 1 ·
Ages: 50 Years to 85 Years ·
Sex: All (male and female) · 1 location
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 9 locations
-
Stem Cell Therapy for Early Alzheimer's Disease
NCT06775964 ·
Phase: Phase 1, Phase 2 ·
Ages: 60 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
Study Safety and Efficacy of Deep Brain Stimulation (DBS) and Cervical Deep Lymphoid-venous Anastomosis (LVA) in Alzheimer's Disease
NCT07094438 ·
Phase: Phase 1 ·
Ages: 40 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
NCT07221344 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 3 locations
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
NCT06548191 ·
Phase: Phase 1 ·
Ages: 60 Years and older ·
Sex: All (male and female) · 1 location
-
The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease
NCT07457125 ·
Phase: Phase 1, Phase 2 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 1 location
-
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
NCT03809351 ·
Phase: Phase 1 ·
Ages: 50 Years and older ·
Sex: All (male and female) · 1 location